Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27289361
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27289361
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Int+J+Hematol
2016 ; 104
(1
): 29-41
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Gene and virotherapy for hematological malignancies
#MMPMID27289361
Domingo-Musibay E
; Yamamoto M
Int J Hematol
2016[Jul]; 104
(1
): 29-41
PMID27289361
show ga
Recent years have seen a transformation in the treatment of hematological
malignancies. Advances in gene therapy and molecular techniques and significant
gains in computational abilities have supported the rapid development of safer
and better tolerated therapies for many patients with hematologic cancers. In
this review, we discuss novel applications of gene therapy, including
immunomodulation and gene silencing, and report on the rise of oncolytic viruses
for use in the treatment of malignancies arising in cells of the blood, lymph,
and marrow. We discuss the relationship of the tropism of wildtype viruses and
their oncolytic behavior as well as the tumoricidal and immunostimulatory
properties of a number of attenuated and recombinant viruses currently in
clinical development in countries around the world. While we have focused on
promising virotherapy applications for future development, we also present a
historical perspective and identify areas of potential clinical and regulatory
practice change. We outline several of the virus systems being developed for
applications in hematology, and summarize efficacy data in the context of ongoing
or future human clinical testing. We also present the advantages and limitations
of gene and virus therapy, including challenges and opportunities for improved
treatment tolerability and outcomes for patients with hematologic malignancies.
free
free
free
